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Background: Longitudinal cohort studies of Ebola virus disease (EVD) survivors from the 2014-
2016 West African outbreak have found evidence of Ebola virus (EBOV) and EBOV RNA 
persistence in the bodily fluids of survivors, particularly in semen.  This new evidence has raised the 
possibility of sexual transmission of EBOV by EVD survivors.  The current interim guidance issued 
by the World Health Organization (WHO) recommends safer sex practices for at least 12 months 
after acute disease onset (ADO). However, based on new evidence, these recommendations may 
require revision.   
Objective: The main aim of this article is to present and evaluate evidence on the persistence of 
EBOV in genital fluids, as determined by RT-PCR or viral isolation.  In addition to determining the 
length of persistence in these genital fluids, the relation of persistence to sexual transmission of EBOV 
is also examined.   
Design: We conducted a systematic review of viral persistence in semen, vaginal, and rectal fluids, 
and assessed evidence of the potential transmissibility of persistent EBOV via sexual transmission 
from survivors.  
Results: We identified 42 published original studies presenting results on EBOV persistence or 
reporting on suspected sexual transmission of EBOV from survivors. EBOV RNA has been detected 
in the seminal fluids of an EVD survivor for up to 40 months post-EVD onset.  From a cohort of 
nearly 2,000 male survivors, we estimate an average length of EBOV RNA duration of 370 days.  
EBOV has also been detected by viral isolation for up to 82 days. Finally, we report that age is a 
potential determinant of EBOV persistence, with older age associated with a higher likelihood of 
EBOV RNA detection in seminal fluid. 
Conclusion: On the basis of the evidence reviewed, we conclude that persistence of EBOV RNA is 
related to an increased risk of sexual transmission of EBOV, though the evidence remains mixed on 
whether detectable EBOV RNA necessarily signifies the presence of infectious virus.  Due to reports 
of intermittent detection of EBOV RNA, especially among survivors who experience EBOV 
persistence for over a year, we recommend that at least two negative RT-PCR results be received 
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Ebola virus (EBOV) and Ebola virus disease (EVD) 
Since the Ebola virus (EBOV) was first discovered in 1976, the 2014—2016 Ebola virus 
disease (EVD) outbreak in West Africa was the largest and most complex Ebola outbreak ever seen.  
This outbreak caused more cases and deaths than all previous outbreaks combined.  The ongoing 
outbreak in the Democratic Republic of the Congo (DRC, formerly the Republic of Zaire), which has 
been responsible so far for a total of 823 cases and 517 deaths as of 12 February 2019,1 is currently 
the largest outbreak of Ebola in the country’s history. This current outbreak, in combination with the 
West African epidemic, has generated a cohort of survivors of unprecedented size.  Due to the high 
case fatality (CFR) of EVD and the limited number of survivors generated by far smaller epidemics 
prior to 2014, little is known about the long-term health impacts of EBOV infection on survivors.  
Furthermore, the recognition that EBOV can persist within various immune-privileged sites of the 
body, and on occasion be transmitted after long periods of time following “recovery” from acute 
disease onset (ADO), has significant public health implications.  Although EBOV transmission via 
persistently-infected individuals is most often chronicled by partners engaging in sexual activity, the 
potential for EBOV resurgence from such events, after successful EBOV control has been declared 
within a country, is of significant concern.  
 
Transmission & Evidence of Persistence of EBOV RNA in Bodily Fluids 
Fruit bats of the Pteropodidae family are thought to be natural reservoirs of filoviruses, including 
EBOV.  However, the evidence for a bat reservoir for EBOV is limited to the identification of viral 
RNA in tissues obtained from several bat species.2 
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The initial introduction of EBOV into humans, prior to subsequent human-to-human 
transmission, is believed to occur from interspecies transmission following exposures to “bushmeat” 
through butchering or consumption of infected tissues.3 Subsequent human-to-human EBOV 
transmission requires close contact with patient blood, vomitus, feces, and fomites (e.g. surfaces and 
materials such as bedding) contaminated with these fluids.3  During acute infection, EBOV RNA is 
also present in sweat, saliva, and tears.4  
EBOV was first isolated in 1976 from seminal fluids of a victim of a laboratory accident. The 
virus could be isolated by viral culture from a semen specimen until day 61 after ADO.5 However, 
EBOV failed to be isolated after day 76 post EVD-onset. 
There is an increasing amount of evidence indicating that EBOV can persist for more than 9 
months after clearance of viremia in a number of bodily sites, leading to shedding of the virus in bodily 
fluids.  Notably, EBOV has been detected by viral isolation or RT-PCR in specimens from immune-
privileged bodily sites such as the testes, the eye, or the central nervous system, which means that the 
presence of antigens can be tolerated in these sites without triggering an immune response. This new 
evidence provokes the possibility of transmission during the long convalescent period.6-9 Since 2015, 
ongoing survivor cohort studies in the three most affected countries of the West African outbreak 
(Guinea, Sierra Leone, and Liberia) have been investigating the persistence of EBOV RNA and EBOV 
by isolation in semen and other bodily fluids in asymptomatic EVD survivors.   
Studies have demonstrated that EBOV can be isolated from semen up to 82 days after 
symptom onset,8 and recent viral persistence studies have used nucleic acid amplification tests such as 
reverse transcriptase polymerase chain reaction (RT-PCR), to detect genetic material (RNA) from 
EBOV up to 965 days (32 months) after ADO.10  These outliers are well beyond the period that 
EBOV can be detected in the blood of EVD survivors and long after recovery from illness.  The 
 
 8 
persistence of viral genetic material months after symptom onset may reflect the presence of live and 
potentially transmissible EBOV. 
Although EBOV RNA has been detected by RT-PCR in vaginal fluid from one woman 33 
days after symptom onset,8 live virus has never been isolated from vaginal fluid samples. Research on 
viral persistence that was conducted after the 2014-2016 EVD outbreak has been unable to 
demonstrate the persistence of EBOV in vaginal fluids.  With such limited data, it remains unknown 
for how long EBOV can typically persist in vaginal fluids. 
 
Evidence of EBOV Sexual Transmission 
During the 1967 outbreak of the Marburg filovirus, a close relative of EBOV, a single instance 
of heterosexual transmission was documented from a male survivor to female partner, suggesting that 
sexual transmission of EBOV could also be possible.11  Since the 2014-2016 outbreak of EVD in West 
Africa, male-to-female transmission of EBOV following exposure to the infected semen of the 
survivor has been reported or suspected in over 15 instances.12,13  In one such instance from March 
2015, EBOV RNA was detected in the semen of a male EVD survivor 199 days after ADO when his 
partner fell ill with acute EVD without a reported exposure to another acute EVD case. Matching of 
genetic sequences strongly suggested that the route of transmission was sexual.14,15  Female to male 
transmission of EBOV is theoretically possible, but seems to be less probable, given the limited 
evidence of persistence of EBOV in vaginal fluids. 
Den Boon et al. defined viral persistence-derived transmission of EBOV as person-to-person 
transmission from an EVD survivor to another person that occurred more than 21 days.16 The 21-day 
period was chosen to reflect the upper limit of EVD’s incubation period.3  This definition of viral 





For EVD survivors, viral persistence in bodily fluids has potentially significant consequences 
for public health guidance.  The current interim guidance issued by the World Health Organization 
(WHO) recommends safer sex practices for at least 12 months after ADO and apparent recovery.17  
The recommended safer sex practices include abstinence from all types of sex or the correct and 
consistent usage of a latex condom during any sexual activity.  However, these recommendations were 
based on studies or reports that had been published up to April 2016, and since then, multiple research 
and national semen testing programs have produced additional evidence that must also be considered. 
A comprehensive search on both existing literature and unpublished resources can yield important 
data on viral persistence in bodily fluids related to sexual transmission that can be used to inform 
decisions on public health recommendations for survivors of EVD.  The WHO defines an EVD 
survivor as a person with a confirmed positive result by RT-PCR testing for EBOV from any bodily 
fluid specimen who has subsequently recovered.18  The definition of an EVD survivor can also include 
someone who is IgM and/or IgG positive for serological testing of EVD, but has not been vaccinated 
against EVD.  The term “convalescent” is also used in EBOV literature to describe EVD survivors. 
In this review, the terms “convalescent” and “survivor” are used interchangeably.  
The primary aim of this article is to present a systematic review on the existing literature 
surrounding the persistence of EBOV in bodily fluids related to sexual transmission, particularly 
semen, vaginal, and rectal fluids.  In addition to determining the length of persistence in these genital 
fluids, the relation of persistence to sexual transmission of EBOV is also examined.  The ultimate goal 
of this systematic review is to provide evidence-based recommendations for revisions of current 








Searches were performed in Medline, Embase, Pubmed, Scopus, and CAB Global Health, as 
well as in the grey literature sources ClinicalTrials and the WHO International Clinical Trials Registry 
Platform.  The searches were conducted from 3 to 5 April 2019, with no restrictions on date, language, 
or limitations related to study design or geographic location. 
The search strategy included medical subject headings (MeSH) and key words for Ebola, in 
combination with MeSH and key words for sexual transmission, barrier method contraception, and 
body fluids, including semen, rectal, and vaginal secretions.  A separate search strategy was developed 
to answer three questions relating to EBOV persistence, condom usage, and sexual transmission; these 
strategies are presented in Supplementary Table 1. The main search terms were used in different 
combinations, using the Boolean operators (“AND” and “OR”) and wildcard variants. The search 
strategies were developed in coordination with information scientists at two universities. The search 
terms were adapted to suit the syntax of each database, and searches with these defined key words 
were limited to the title, keywords, or abstract of the article.  
 
Inclusion Criteria 
Since the aim was to find published and unpublished primary data on EBOV persistence in 
body fluids and the relation of persistence to sexual transmission, we excluded commentaries, 
editorials, protocols, and news reports. Eligible studies included randomized controlled trials (RCTs), 
non-randomized controlled trials, controlled before and after studies, interrupted time series, cohort 




Titles and abstracts were screened for inclusion criteria by a single reviewer. If the abstract 
was unavailable, the full text of the article was only assessed if the title included at least one of the 
following key words or its variations: survivor, convalescence, fluids, persistence, semen, vaginal, condom, 
contraception, or sexual transmission.  Following the screening of titles and abstracts, the full texts of 
relevant articles were then examined by the same reviewer.  Papers that met the aforementioned 
inclusion criteria were included in the final review.  To ensure that primary data points were not 
duplicated, articles that reported on the same patient results were grouped together. 
Each included study was validated through the creation of a validation assessment table 
(Supplementary Table 2).  Cases of EBOV infection that were deemed relevant to this review necessitated 
laboratory confirmation of a positive EBOV result via viral culture or RT-PCR assay. The presence 
of antibodies and other post-disease markers in body fluids were not considered eligible by themselves, 
as they only confirm a prior exposure or recovery from acute EBOV infection.  Prior studies have 
shown that antibodies are widespread in regional populations, including those with no relevant clinical 
history.19-21  Each study was assessed based on whether its assay methods were appropriate and 
validated, samples were duplicate-tested or compared to controls, and that samples were collected and 
stored for a relatively short period of time prior to testing (less than 2 weeks in order to minimize risks 
of specimen degradation, unless stored at -80°C or in dry ice or liquid nitrogen).  
Data were extracted from the included studies by the same reviewer. Details extracted from 
each article included the following: author, year, study setting, reports of sexual transmission from 
survivors of EBOV infection, and length of EBOV persistence in body fluids of interest, as evidenced 








Following de-duplication, 706 unique articles were found in Medline, Embase, Pubmed, 
Scopus, and CAB Global Health (Fig. 1), and 17 items were found from grey literature on clinical trials. 
Of these 723 references included in the title and abstract screening, 148 references were chosen for 
full-text review.  Seven of these were articles that were cited by relevant studies but not found during 
the database search were thus also included in full text review. These articles typically did not show 
up in the initial database search because they did not cite the genital fluids of interest in their titles or 
abstracts, as screening of genital fluids of EBOV was not the main objective of these studies. After 
excluding articles that did not meet the inclusion criteria (n=106), 42 studies were included in the 
study. Data were extracted from these articles, and a validity assessment was performed on each study 
(Supplementary Table 2). 
 




Part 1: Evidence of EBOV Persistence in Genital Fluids 
 
Data on the persistence of EBOV in the genital fluids of convalescents have been amassed 
over four EBOV outbreaks, including a 1976 laboratory accident in the United Kingdom, the 1995 
outbreak in Kikwit, Democratic Republic of the Congo (DRC), the Sudan EBOV outbreak in 2000 
in Gulu, Uganda, and the 2014-2016 West African outbreak. Published data relevant to this review 
does not yet exist from the May 2018 outbreak in Équateur province, DRC, or for the current outbreak 
in the North Kivu and Ituri provinces of the DRC.  Rectal samples were also considered in this study, 
as the anus may also be involved in sexual activity. 
A total of 25 studies reported data on EBOV persistence in genital and rectal fluids; these 
results are summarized in Table 1. While a number of studies were case reports of a single patient, 11 
studies reported on large cohort studies of at least 100 EBOV survivors from Sierra Leone, Guinea, 
and Liberia during the 2014-2016 West African outbreak. The most commonly used assay to detect 
persistence of EBOV in genital fluids was RT-PCR, and most studies defined a positive test as one 
with cycle thresholds (Ct) of less than 40 for both viral targets NP and VP40. A result was considered 
indeterminant if only one viral target was detected, with the exception of Fischer et al., who considered 
any result to be positive if either gene target was detected.22  A prior study by Fischer et al. validated 
the use of RT-PCR as an assay for detecting EBOV RNA in body fluid samples.23 
 
Evidence of EBOV Persistence in Semen   
The average duration of time for which EBOV RNA was detectable in semen, which was 
measured as the number of days to the last positive semen sample, was 370.3 days (standard deviation 
= 345.1, n = 448). The persistence of EBOV RNA in semen was calculated as a weighted average of 
studies that had provided either individual data or information on mean time between disease onset 
and last positive sample (Supplementary Table 3).  Some studies reported the duration of EBOV RNA 
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persistence as days since discharge from an Ebola treatment center instead of days from ADO.24-26 To 
standardize for this discrepancy during analysis, 14 days were added to these measures to account for 
the period of time between ADO and recovery from EVD.  Since no estimate for the average length 
of recovery from EVD currently exists, the 14 day-estimate was determined using evidence from 
several EVD case studies from the 2014-2016 West African outbreak.27-29 
Out of 1,926 total convalescents from 25 studies who provided semen specimens, 315 (16.4%) 
had at least one positive semen specimen.  The longest duration of detection of EBOV RNA was 
roughly 40 months, as reported by the Partnership for Research on Ebola Virus in Liberia (PREVAIL 
III) cohort study.30  In the PREVAIL III cohort study, 267 male EVD survivors provided a total of 
2,416 semen sample. The time from ADO to collection of the first sample ranged from 233 to 1,173 
days (median = 551 days). EBOV RNA was detected in at least one semen sample for 81 men 
(30.3%).30   
Other large cohort studies similarly detected EBOV RNA in seminal fluids of survivors for 
over a year after EVD onset (Fig. 2). A study of EVD survivors enrolled in the National Semen Testing 
Program in Liberia detected EBOV RNA in the semen of 57 survivors of the 210 survivors (27.1%) 
who provided samples.6 The last positive semen sample in the PREVAIL III study was reported at 
470 days post-recovery. Another cohort study of male Liberian survivors detected at least one positive 
EBOV RNA semen sample in 13 out of 149 survivors (8.7%), with the longest duration of persistence 
at 965 days after ADO.22 Similarly, the Postebogui survivors’ cohort study in Guinea found that only 
15 of 188 survivors who provided semen samples (8.0%) had at least one semen sample positive for 
EBOV RNA.24 The last positive semen sample from the Postebogui cohort was collected 548 days 
after the survivor’s recovery.25,31 The Sierra Leone Ebola Virus Persistence Study (VPS) found that 15 
out of 120 survivors (12.5%) tested positive for EBOV RNA in at least one semen sample, with the 
longest duration of persistence at 406 days after ADO.32  






























Abel et al (2017)24 Semen RT-PCR 188 15 (8.0) 409 190.4 ± 
155.1* 
497* 518* 
Barnes et al (2017)33 Semen RT-PCR 1 1 (100.0) 5 
 
110 180  
Barnes et al (2017)33 Semen Viral 
isolation 
1 1 (100.0) 5  37  
Bausch et al (2007)4 Semen RT-PCR 1 1 (100.0) 2 
 
40 45 
Bausch et al (2007)4  Semen Viral 
isolation 




Christie et al 
(2015),14 Mate et al 
(2015)15 
Semen RT-PCR 1 1 (100.0) 1 
 
199 231 
Christie et al (2015)14 Semen Viral 
isolation 




Deen et al (2017)6 Semen RT-PCR 210 57 (27.1) 210 Not reported 470* 100* 
Diallo et al (2016)7 Semen RT-PCR 1 1 (100.0) Not reported 
 
531 Not done 
Emond et al (1977)5 Semen Viral 
isolation 
1 1 (100.0) 5 
 
61 76 




548* Not done 




Fallah et al (2016)34 Semen RT-PCR 76 28 (36.8) 76-304 Not reported 488 Not reported 
Fischer et al (2017)22 Semen RT-PCR 149 13 (8.7) 
 
771.9 ± 100.9 965 
 












Knust et al (2016)32 Semen RT-PCR 120 15 (12.5) 
 
Not reported 406 
 






























Knust et al (2016)32 Semen Viral 
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PREVAIL III Study 
Group (2019)30 
Semen RT-PCR 267 81 (30.3) 2411 Not reported 40 months 
(~1200 days) 
 
Purpura et al (2017)36 Semen RT-PCR 1 1 (100.0) 
  
565* 603* 








Rodriguez et al 
(1999),8 Rowe et al 
(1999)38 
Semen RT-PCR 5 4 (80.0) 11 85.8 ± 17.2 101 62 
Rodriguez et al 
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Rodriguez et al 
(1999)8 
Rectal RT-PCR 8 1 (12.5) 19 
 
29 33 




Rowe et al (1999)38 Vaginal Viral 
isolation 




Sissoko et al (2017)9 Semen RT-PCR 26 19 (73.1) 130 149.6 ± 91.2 407 
 
Sissoko et al (2017)39 Semen RT-PCR 1 1 (100.0) 
  
Sep 15, 2015 Oct 7, 2015 
Soka et al (2016)40 Semen RT-PCR 429 38 (8.9) 
 
Not reported 565* 
 
Sow et al (2016)41 Semen RT-PCR 68 8 (11.8) 98 118.9 ± 79.9 276 
 


































Srinivas et al (2016)26 Semen Viral 
isolation 




Subtil et al (2017)31 Semen RT-PCR 188 15 (8.0) 409 231.5 (min 29 
- max 551) 
551 
 
Uyeki et al (2016)42 Semen RT-PCR 5 5 (100.0) 25 184.6 ± 75.3 290 222 
Uyeki et al (2016)42 Semen Viral 
isolation 




Note: * denotes that this value was measured as days after discharge from an Ebola treatment center (ETC)
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Figure 2. Bubble chart depicting average duration of EBOV persistence, as measured by 






Detection of EBOV by RT-PCR vs. Viral Isolation in Semen 
Though many studies have reported persistence of EBOV RNA in the body fluids of 
survivors, the presence of EBOV RNA does not necessarily imply the presence of infectious virus.  
In order to establish an association between detection of EBOV RNA by RT-PCR and the presence 
of infectious virus, a few studies have attempted to detect EBOV by both RT-PCR and viral isolation 







Figure 3. Bar chart comparing duration of EBOV persistence between viral isolation and 
RT-PCR methods, for studies that attempted both assays on the same samples 
Note: * denotes that this value was measured as days after discharge from an ETC; † denotes that 







Only five studies were successful in isolating EBOV by viral culture for samples that were 
positive for EBOV RNA by RT-PCR.4,5,8,33,42  From these viral culture assays, the longest duration of 
persistence of EBOV in seminal fluids of survivors was found to be 82 days after ADO.8  In 
comparing the duration of EBOV persistence detectable between these two assays, three studies found 
that EBOV RNA could be detected by RT-PCR longer than EBOV could be detected by viral culture 
(101 days by RT-PCR vs. 82 days by viral culture,8 290 days by RT-PCR vs. 70 days by viral culture42, 
and 110 days by RT-PCR vs. 37 days by viral culture33).  The fourth study found the same duration of 
EBOV persistence by both RT-PCR and viral culture,4 and the last study only used viral culture to 
detect EBOV.5  An abstract from the VPS cohort stated that of the four semen specimens that yielded 
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EBOV isolates by viral culture, the longest duration post-EVD onset that viable EBOV was detected 
was 157 days.32 This study result was not reported in any other full-text article.  Several other studies 
also attempted to detect EBOV by viral culture; however, these studies were unsuccessful.14,15,26,38  
 
Evidence of EBOV Persistence in Vaginal & Rectal Specimens 
A total of 321 female survivors of EBOV across 5 studies provided vaginal fluid specimens 
via vaginal swabs. Only 2 survivors (0.6%) tested positive for EBOV RNA by RT-PCR,8,32 and the last 
positive vaginal fluid sample was collected 35 days after ADO (Fig. 2).32  Viral cultures were attempted 
from vaginal fluid specimens from 25 survivors up until day 33 after ADO, none of which were 
successful.8,38  Out of 25 patients for which rectal specimens were collected,43 only one female survivor 
had specimens that were positive by RT-PCR until day 29 after symptom onset, but negative by day 
33.8 Viral isolation was not attempted on this sample. 
 
Persistence in Semen by Age 
A longitudinal cohort study of EVD survivors in Monrovia, Liberia followed 149 male 
survivors who donated semen samples from 260 to 1016 days after ADO.22  The study observed that 
older male survivors were significantly more likely to have detectable EBOV RNA in seminal fluids 
(median age 41.8 vs 31.2 years, p = 0.0004).  Similarly, the Liberia Men’s Health Screening Program, 
which provides semen testing services to EVD survivors, found that survivors over the age of 40 
comprised 50% of participants with at least one semen sample testing positive for EBOV RNA, 
despite accounting for only 23% of the male survivor population in this cohort.40  In one study of 
male survivors in Guinea, whose semen specimens were first tested between one to twelve months 
after EVD onset, EBOV persistence in semen was detected in eight out of 68 survivors (11%).41 Of 
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these 8, the duration of EBOV persistence in seminal fluids averaged 225 days post disease onset for 
men over the age of 40, compared to 67.8 days for men under 40.   
However, a relation between the duration of persistence and survivor age has not been 
universally identified. In a longitudinal study of 26 participants in Guinea, the duration of EBOV 
persistence in men older than 40 and in men younger than 40 differed by only 12 days, with older men 
experiencing longer persistence.9 
In order to elucidate the relation between persistence of EBOV RNA and survivor age, we 
extracted data on the participants’ ages at ADO and the number of days between EVD onset and the 
last positive EBOV RNA RT-PCR in seminal samples.  Eighteen of the 25 studies reported on these 
two variables, supplying a total of 54 data points for analysis (Supplementary Table 4). Linear regression 
indicated that age was a statistically significant predictor for the duration of EBOV RNA persistence 
in semen (p = 0.0003, n = 54), with a positive correlation between age and the duration of persistence 




Table 2. Linear Regression Output for Age & Duration of Persistence  
 
Duration of persistence = -146.47 + 12.90(Age) 






Intercept -146.47 124.85 -1.17 0.25 
 
Age 12.90 3.32 3.88 0.000296 ***       
Residual standard 
error 
256.8 on 52 degrees of freedom 
  
Adjusted R-squared 0.2096 
    











Intermittent Detection of EBOV RNA in Semen 
Several studies have reported intermittent detection of EBOV RNA in semen, with samples 
fluctuating between negative and positive results when survivors provided additional samples for 
testing over several weeks or months (Fig. 5a, 5b). The Postebogui cohort study in Guinea found that 
of the 15 men who had at least one semen sample positive for EBOV RNA, 8 men (53.3%) 
experienced fluctuating negative and positive results over multiple days.24,31  For instance, one man 
tested negative on day 397 after recovery, positive on day 453, and negative once again on day 463. 
Another cohort study of survivors in Liberia found that 8 out of 13 men (61.5%) with positive results 
demonstrated intermittent detection of EBOV RNA in seminal fluids, with a positive PCR result 
preceded by at least one negative result.22 Of these eight, one participant initially had two negative 
samples before a third sample tested positive for EBOV RNA.  Similarly, in the PREVAIL III cohort 
study, intermittent detection of viral RNA was observed in 78 of the 252 men who provided a semen 
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sample (31.0%); 36 of these participants (14.2%) also had two negative PCR tests followed by a 
positive.  A case study of an EVD survivor from Liberia also reported two negative PCR tests followed 
by a positive result.36  
Each study also used different brands of RT-PCR assays. Of the studies that reported 
intermittent results, the RealStar Filovirus Screen RT-PCR,24,31 the Cepheid Xpert Ebola RT-PCR,22 
and the CDC’s Ebola Virus Real-Time RT-PCR36 assays were used.  Of the studies that did not report 
intermittent results, the EZ1 Real-Time RT-PCR33 and the RealStar Zaire EBOV RT-PCR9 assays 
were used.  Christie et al. and Mate et al. did not report on which RT-PCR assay was used.14,15 
 
Figure 5a. Survivors with multiple semen samples demonstrating intermittent detection of 
EBOV RNA by RT-PCR. Green boxes represent positive tests, while red boxes represent negative 
tests.  The numbers in each cell indicate the day post-EVD onset on which the sample was collected 
and tested. Survivors were included in this figure if individual-level data on RT-PCR results were 
provided by the study authors. Authors who provided this data include Abel et al. (2017), Fischer et 





Figure 5b. Survivors with multiple semen samples that did not demonstrate intermittent 
detection of EBOV RNA by RT-PCR. Survivors were included in this figure if individual-level 
data on RT-PCR results showed that negative results were retested. Authors who provided this data 




In order to calculate an overall proportion of EVD survivors whose RT-PCR results yielded 
intermittent detection of EBOV RNA in seminal fluid, studies that retested negative RT-PCR samples 
but did not find fluctuating persistence were included alongside the studies that reported intermittent 
detection. In other words, if a study continued testing semen samples even after one negative sample 
was received, the study was included in this analysis. This choice was made because many other studies 
on EBOV persistence in semen stopped testing participants’ samples after a single negative RT-PCR 
result was received; however, these studies might have missed detection of fluctuating persistence 
since these negative samples were not retested.  Based on this criterion, 9 studies were eligible for this 
analysis (Supplementary Table 5), with a total of 303 participants.  Intermittent detection of EBOV RNA 
was detected in 95 survivors’ seminal samples (31.4%); 38 (12.5%) experienced two negative PCR tests 
followed by a positive.  
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The samples from these 9 studies on EBOV persistence in seminal samples were then 
compared by the following: (1) day post-EVD onset of the last positive EBOV RT-PCR result in 
seminal samples, (2) day post-EVD onset of the first “true” negative EBOV result in seminal samples, 
(3) total duration of follow-up time for each individual (as calculated by the date of the first sample 
subtracted from the date of the last sample), and (4) duration of follow-up time from the last positive 
EBOV result to the last sample.  In this analysis, a negative RT-PCR result was considered to be a 
“true” negative if this result was followed by a second negative RT-PCR result with an interval of at 
least one week between tests. Although less than 13% of individuals experienced two negative RT-
PCR results followed by a positive, current WHO interim guidelines denote that a person is no longer 
at risk of sexual transmission of EBOV after two negative tests of semen by RT-PCR.18  Data on these 
individual variables can be found in the supplement (Supplementary Tables 6a, 6b). To compare samples 
with and without intermittent detection of EBOV RNA, Welch’s two-sample t-test for difference of 
means was performed for each of these 4 variables.  
This analysis found that the studies with intermittent detection of EBOV RNA had a 
statistically significant higher average day of last positive sample (639.2 ± 230.0 days) compared to 
participants whose samples did not exhibit intermittent detection (129.6 ± 71.4 days, p-value = 
<0.001). Similarly, the samples with intermittent detection had a statistically significant higher average 
day of first “true” negative sample (709.2 ± 261.2 days) compared to samples without intermittent 
detection (239.3 ± 68.1 days, p-value = <0.001). Average duration of follow-up time was significantly 
higher for samples with intermittent detection (260.8 ± 98.9 days) than for samples where intermittent 
detection was not observed (115.9 ± 58.0 days, p-value = <0.001). However, for the duration of 
follow-up time from the last positive result to the last sample, there was no significant difference 
between samples that did observe intermittent detection (159.8 ± 106.1 days) and those that did not 
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Table 3. Welch’s Two Sample T-Test for Difference in Means for Intermittent Detection of 
EBOV RNA in Semen 
  
Mean ± SD 

























129.6 ± 71.4 (360.5, 
658.6) 
7.41 12.6 6.15E-06 







239.3 ± 68.1 (301.7, 
638.2) 





260.8 ± 98.9 115.9 ± 58.0 (77.1, 
212.5) 









109.7 ± 53.8 (-21.1, 
121.3) 
1.50 15.2 0.154 
 
* A negative RT-PCR result was considered to be a “true” negative if this result was followed by a 
second negative RT-PCR result with an interval of at least one week between tests 
 
 
Modelling Studies on Duration of EBOV Persistence in Semen 
A few modelling studies on the persistence of EBOV in semen have been conducted using 
viral persistence data from existing cohort studies. One such study fitted a negative binomial 
distribution to viral persistence data from a cohort study of 220 adult male survivors in Sierra Leone,6 
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combined with weekly disease incidence data from the WHO patient database for Guinea, Liberia, 
and Sierra Leone.44  The fitted distribution was used to estimate the number of men in each country 
with EBOV RNA detectable in semen for each week, starting from mid-2014. The model projected 
that by January 2016, the total number of EBOV RNA semen-positive individuals would decrease 
from 2,255 people (95% CI: 1,945-2,495) in January 2015 to just 73 people (95% CI: 15-331) across 
all 3 countries by January 2016.44  Another study applied parametric survival models to data from the 
Postebogui cohort study in Guinea to estimate the time elapsed between ADO and when EBOV 
RNA was no longer detectable in semen by RT-PCR.31  The median time from symptom onset to a 
negative RT-PCR test was 46.4 (95% CI: 11-82.6) days. The probability of a survivor’s semen sample 
testing positive by RT-PCR decreased from 31.6% at 3 months to  2.9% and 0.7% at 12 and 18 months 
post EVD-onset, respectively.31 
Time-series data from a longitudinal study of 26 EVD survivors in Guinea were used to model 
the dynamics of EBOV persistence in semen over time.9  The linear mixed-effect model, which used 
parameters for a hypothetical baseline Ct value at the time of ADO and a clearance rate of EBOV 
from semen, predicted that 50% of male survivors would clear EBOV RNA from seminal fluid by 
115 days (95% CI: 72-160) post-disease onset and that 90% of male survivors would clear EBOV 
RNA from seminal fluid by 294 days (95% CI: 212-399) post-onset.9   
 
Part 2: Sexual Transmission of EBOV from Convalescents and Subsequent EVD 
 
Although detection of EBOV RNA in genital fluids was first reported by Emond et al.’s case 
study in 1977,5 reports of likely sexual transmission of EBOV from survivors were first documented 
during the 2014-2016 West African outbreak.  While the number of EVD survivors has increased 
dramatically since earlier outbreaks, data on actual sexual transmission of EBOV from EVD survivors 
remain sparse.   
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To date, 19 cases of EBOV transmission from convalescent survivors have been reported in 
the published literature (Table 4). Of these, 14 cases involved either probable or confirmed sexual 
transmission from a male survivor; for the remaining five case, the route of transmission is unknown.  
Confirmation of sexual transmission was determined by a combination of epidemiological 
investigation, genomic sequencing of EBOV samples, and lack of evidence of contact with an 
individual with EVD-related symptoms. The longest duration of detectable EBOV RNA in reported 
cases of sexual transmission was found to be 531 days after ADO.7  At the time of transmission, the 
survivor was 463 days post-EVD onset, which is the longest duration of persistence at the time of 
transmission for the cases in which transmissions dates are known.7  In all cases of probable or 
confirmed sexual transmission, semen was the most probable vehicle for EBOV transmission.  
However, EBOV isolation by viral culture in sexual transmission studies was either not attempted or 
unsuccessful.  For cases in which the transmission date was known or highly probable, onset of EVD 
usually occurred within 3 weeks of transmission from the survivor (mean = 19.8 days, n = 4).  This 
finding is consistent with the incubation period of 2-21 days for EBOV infection through other routes 
of transmission (i.e. contact with infected blood).3 All cases of sexual transmission were from a male 
survivor to their female partner. There were no reports of suspected sexual transmission from a male 
survivor to a male partner or of sexual transmission from a female survivor.  
 
Molecular Evidence of Sexual Transmission 
Advances in molecular typing through the past few decades have allowed researchers to use 
whole-genome sequencing data alongside traditional epidemiological methods to investigate potential 
sources and routes of transmission.  In July 2015, the Ebola Outbreak Sequencing Support (EOSS), a 
collaboration between the Sierra Leone Ministry of Health, the WHO, and the US Centers for Disease 
Control & Prevention (CDC), was established to sequence all new EVD cases in Sierra Leone. 
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Researchers identified a possible instance of sexual transmission from a survivor more than 50 days 
after the last confirmed case in that particular district.45 The EBOV genome from a blood sample 
collected from the new acute case was closely related to the EBOV genome from a male survivor who 
had recovered from EVD about a month earlier. Sexual contact was reported between the male 
survivor and the incident case.  The viral genome obtained from the survivor’s semen during 
investigations into this new cluster was identical to the viral genome of the survivor’s initial blood 
sample, collected 2 months earlier during acute EVD,45 which suggests that the virus was maintained 
in a low replicating state within the survivor, even after recovery from acute EVD.  
Other studies have exploited similarities between genomic sequences of different EBOV 
samples to provide indirect evidence of sexual transmission of EBOV.  Five studies investigated 10 
new clusters of EVD that appeared months after the last reported case in the same geographic area.16,45-
49 While epidemiological investigations into these new clusters failed to identify a source of infection, 
whole-genome sequencing was able to link the EBOV genomes from the new clusters to genomes 
from either a prior circulating strain16,46,47 or from a known survivor,16,45 both of which suggest 
transmission from survivors. 
Table 4. Summary of Reports of Transmission of EBOV from a Convalescent 
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Jan-3, 2016 Unknown Unknown, but 
likely from 
persistence in a 
survivor (from 
genomic data) 
Unknown Unknown N/A 2 >1 Unknown 




Aug-29, 2015 Aug, 2015 (14-
44 days) 
Sexual, probable Semen, 
probable 




Liberia Jun-28, 2015 Jun-1, 2015 Unknown, but 
likely from 
persistence in a 
survivor (from 
genomic data) 

















Mate et al 
(2015)15 
Liberia Mar-20, 2015 Mar-7, 2015 
(151 days) 




Liberia *no transmission despite 3-5 occasions of unprotected vaginal intercourse (between 
Feb-28,2015 – Mar-15,2015) 
 
0 0 N/A 
Den 






Unspecified Unspecified Sexual, probable Semen Unknown ~7 weeks (but 
unspecified) 
1 Unknown Unknown 
Den 






Unspecified ~1-3 weeks 
before 
symptom onset 
Sexual, confirmed Semen, 
probable 
Unspecified 2 months 1 1 Unknown 
Table 4. Summary of Reports of Transmission of EBOV from a Convalescent 
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Unspecified Unknown Unknown, but 
likely from 
persistence in a 
survivor (from 
genomic data) 
Unknown Unknown N/A 1 Unknown Unknown 
Den 






Unspecified Unknown Unknown, but 
likely from 
persistence in a 
survivor (from 
genomic data) 
Unknown N/A ~5 months 
(but 
unspecified) 
1 1 Unknown 
Den 






Unspecified Unknown Sexual, probable Semen, 
probable 
Unknown ~5-6 months 
(but 
unspecified) 
1 1 Unknown 
Diallo et 
al (2016)7 
Guinea Mar-16, 2016 Feb-20, 2016 
(463 days) 
Sexual, confirmed Semen Nov-14, 
2014 










likely via bodily 
fluids or close 
contact 
Unknown Aug, 2014 Unknown 2 1 Unknown 
Keita et al 
(2016)49 
Guinea Oct-13, 2015 Unknown Unknown, but 
likely close 
contact with body 
fluids* (but sexual 
transmission 
from survivor to 
wife, then from 
wife to brother 




Dec, 2014 Unknown 2 0 Not 
attempted 
Lee et al 
(2017)50 
Liberia Jun-29, 2015 Unknown Sexual, probable Unknown Jan-16, 2015 164 days 1 Unknown Unknown 
Lee et al 
(2017)50 
Guinea Mar-17, 2016 Unknown Sexual, probable Semen, 
probable 
Unknown 140 days 1 Unknown Unknown 
Table 4. Summary of Reports of Transmission of EBOV from a Convalescent 
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Jan-14, 2016 Unknown Sexual, probable Semen, 
probable 









Liberia Unspecified Unknown Sexual, probable Semen, 
probable 




Liberia Unspecified Unknown Sexual, probable Semen, 
probable 




Liberia ~Nov, 2014 
(but 
unspecified) 
Unknown Sexual, probable Semen, 
probable 
Unknown Unknown 1 Unknown Unknown 
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A prior study by Rodriguez et al. tested the genomic stability of EBOV by sequencing a highly 
variable region of the GP gene, which encodes for a viral envelope glycoprotein, in multiple samples.8  
These samples were chosen from patients who were known to be within the same chain of direct 
human-human transmission.  The authors found that samples demonstrated high sequence similarity 
for this highly variable region, suggesting that similarities in EBOV genomes between two different 
patients may be indicative of direct transmission.8 Based on the Rodriguez et al. study findings, several 
studies that had previously identified a convalescent survivor as the source of infection for an incident 
EVD case through an epidemiological investigation were able to compare EBOV genome sequences 
between the convalescent and incident cases. Sequencing data from these studies found a high level 
of similarity in the EBOV genome, suggesting that sexual transmission did indeed occur.7,14-16,39,48,49 
In transmission reports in which a specific survivor was identified as the source of infection, 
researchers observed reduced rates of EBOV evolution during persistent infection, despite months or 
even years of elapsed time between samples. For instance, the EBOV genome from one survivor’s 
blood sample during acute infection differed from that in his semen sample by only 5 nucleotide 
substitutions, despite being collected 504 days prior to the collection of the semen sample.7  The 
resulting evolutionary rate for this convalescent semen sample was roughly 6 times slower than that 
of the average evolutionary rate seen in acute human-to-human transmission in the West African 
outbreak.7  This finding, along with similar results in other studies,15,45,47,49 suggests that persistent 
EBOV exhibits reduced evolutionary rates in survivors.  
Barnes et al. reported EBOV RNA detected by RT-PCR from a 34-year-old survivor from 
Sierra Leone, whose seminal fluid was RT-PCR positive 110 days after ADO.33  To determine whether 
the EBOV in the semen sample was actively replicating within cells or if it persisted only as 
extracellular virions, the authors used strand-specific RNA methods to compare levels of genomic 
viral RNA versus viral antigenomic RNA (cRNA) and messenger RNA (mRNA). The levels of cRNA 
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and mRNA detected in samples from 32 days to 110 days after ADO were similar to the levels found 
in acute-EVD blood samples, suggesting active viral replication the survivors’ semen. Barnes et al. not 
only reported high concentrations of replication-competent virus in semen, but also decreased viral 
diversification during persistence.33   
 
Modelling Studies on EBOV Sexual Transmission by Convalescents 
To quantify the importance of EBOV viral persistence-related sexual transmission in 
increasing the number of cases and duration of the epidemic, several studies developed models that 
accounted for sexual transmission from convalescent survivors. One model used weekly incidence 
data from EVD cases in Sierra Leone and found that, for a fixed 0.1% transmission probability per 
sexual contact, a 3-month duration of EBOV persistence created very few additional cases but 
extended the epidemic by 83 days on average.52 They estimated that a 6-month duration of EBOV 
persistence extended the epidemic by 540 days, which was double the length of the 2014-2015 Sierra 
Leone Ebola epidemic.52  Another modelling study found that sexual transmission by convalescents 
is a significant factor in determining the risk of EVD recurrence in areas that were previously declared 
transmission free.53 The authors reported that public health officials may need to wait up to one year 
after the last EVD case before declaring the end of the epidemic, though this wait time could decrease 
if survivors routinely practice safer sex or sexual abstinence.53  A modelling study on EVD intervention 
efficacies fit an SIR compartmental model to predictive EVD transmission patterns and found that 
post-recovery condom usage by all recovered patients could reduce the number of EVD cases by 26% 
and shift the peak of the epidemic curve earlier by 19 days.54  Another study used daily cumulative 
cases from West Africa to fit a compartmental model that considered contact with infectious 
individuals, contact with dead bodies, and sexual transmission from convalescent survivors; the 
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authors found that sexual contact with convalescent patients had significant effects on increasing the 
basic reproduction number R0.55  
 
Animal Studies of Sexual Transmission Potential 
A study on the transmission potential of persistently-infected survivors inoculated 
immunodeficient mice with semen samples from eight convalescents who had previously tested 
positive for EBOV RNA by RT-PCR.9  Infectious virus was detected by culture in 15 out of 26 (58%) 
specimens that were tested in the mice, and these mice subsequently developed EVD.  Another animal 
model study described EBOV persistence in convalescent rhesus monkeys that were experimentally 
infected. The authors detected EBOV RNA in eye, testicle, or brain tissues in 11 out of 112 survivors 
(9.8%) from samples that were collected 43 days post-exposure.56  In contrast, EBOV RNA was not 
detected in liver, lymph node, or spleen tissues, which are common target tissues during acute EBOV 
infection. Notably, multiplex fluorescence in situ hybridization discovered not only the EBOV 
genome, but also the EBOV antigenome in the eye, epididymis, and brain of survivors, which are 
immune-privileged sites. Taken together, this data suggests ongoing EBOV replication at the time of 
sample collection.56  
 
Prevention of Sexual Transmission through Condom Use by Male EVD Survivors 
The use of condoms by EVD survivors during sexual activity remains inconsistent. Sixty-five 
percent of participants in the Postebogui survivor cohort study in Guinea (n=664) reported sexual 
activity without a condom since recovery, including 48% of those with a semen sample that tested 
positive for EBOV RNA by RT-PCR (n=491).34  Liberia’s Men’s Health Screening Program found 
that 427 of 466 participants (92%) reported being counselled by EVD treatment unit (ETU) staff to 
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either abstain from sexual activity or to use condoms for 90 days post-recovery, as recommended by 
WHO interim guidelines for survivors at the time.40 At the time of enrollment, which ranged from 7 
days to 697 days post-EVD recovery (median = 384 days), 424 (91%) participants reported having 
resumed sexual activity. Of the 410 participants who reported the date that they resumed sexual 
activity, 363 (89%) waited at least 90 days after discharge from an ETU before resuming sexual activity.  
Of the 424 participants who reported resuming sexual activity, 190 (45%) reported using a condom 




This is the first systematic review on the persistence of EBOV in genital fluids and its relation 
to sexual transmission since Thorson et al. in 2016.12 Our review captures recent evidence released by 
national semen testing programs and cohort studies that followed survivors from the 2014-2016 West 
African EVD outbreak.  The WHO’s interim guidelines on clinical care for EVD survivors were last 
revised in April 2016.18 Currently, the WHO recommends safer sex practices for at least 12 months 
for EVD survivors who have not had their semen tested. The evidence reviewed here suggests that 
EBOV can persist in the seminal fluids of survivors for longer than 12 months, which justifies the 
need for a reassessment of these guidelines.  
In this review, we provide quantitative estimates of the length of EBOV persistence in semen, 
vaginal, and rectal fluids and report on the transmission potential of persistent EBOV.  Among almost 
2,000 male EVD survivors, more than 16% had at least one RT-PCR positive semen sample result 
during convalescence or post-recovery, indicating that viral persistence in semen is not a rare 
occurrence.  EBOV RNA was detected in semen by RT-PCR for up to 40 months,30 which far exceeds 
the WHO’s 12-month recommendation for safer sex practices among EVD survivors.  Across studies 
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included in this review, EBOV RNA persisted in semen for an average of 370 days, which also suggests 
the need to reassess the interim WHO guidelines.  Data on viral persistence in semen is right-censored; 
for five studies included in this review, some participants were still RT-PCR positive for EBOV RNA 
in semen when the study ended.22,30,35,41,57  This suggests that the average duration of persistence of 
viral RNA is likely an underestimate. 
Of the more than 300 female survivors whose vaginal fluids were tested for EBOV persistence 
up to 35 days post-EVD onset, less than 1% were RT-PCR positive for EBOV RNA. This low 
proportion is consistent with previous studies of EBOV persistence in vaginal fluids.8,38 The longest 
duration of EBOV RNA persistence was 35 days across the 321 vaginal fluid samples that tested 
positive.32 Similarly, while 25 rectal samples were tested, the last rectal sample tested positive for 
EBOV RNA at 29 days.8  
The detection of EBOV RNA in genital fluids does not necessarily imply that the sample is 
infectious; evidence on the transmission potential of persistent EBOV RNA in genital fluids was also 
evaluated. From studies that attempted viral cultures of RT-PCR positive genital fluid samples, the 
maximum time at which EBOV was isolated was 82 days post-EVD onset from a semen sample.8 No 
EBOV has been successfully isolated from vaginal or rectal samples. Only 5 studies have successfully 
detected EBOV by viral culture in convalescent seminal fluids.4,5,8,33,42 This could be related to the 
small number of studies that attempted viral isolation, to publication bias, or to the inactivation of the 
virus by standard practices of storing and freezing specimens.8 
The most direct link between persistent EBOV RNA detection in seminal fluids and evidence 
of infectiousness was established by Sissoko et al. Seminal fluid specimens from EVD survivors, with 
persistent EBOV RNA detected at a median duration of 158 days after ADO, were inoculated into 
immunodeficient mice.9  Infectious virus was detected in more than half of the specimens tested in 
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the mice. Subsequent EBOV infection of these mice indicates that EBOV RNA detected by RT-PCR 
in seminal fluid may be indicative of infectious viral particles.   
A study by Barnes et al., which used semen samples from a male EVD survivor with EBOV 
RNA detected up to 110 days post-EVD onset, found high concentrations of replication-competent 
virus in viral cultures.33  A consistent result across this study and a number of other studies that 
examined genomic sequencing data was that EBOV RNA exhibited decreased viral diversity during 
persistence, with very few nucleotide substitutions between fluid samples that were collected months, 
and even years, apart.15,33,45,47,49 In other words, in persistent EBOV RNA samples, EBOV can be 
maintained in a low replicating state, but with an evolutionary rate that is reduced compared to that 
seen during acute human-to-human transmission.  To explain the reduced evolutionary rate, Blackley 
et al. and Diallo et al. suggest that EBOV in immune-privileged sites such as the testes might experience 
a reduced rate of viral replication;7,47 persistence of the EBOV RNA could then be explained by the 
characteristic reduction of immune clearance seen in immune-privileged sites.58 However, Barnes et 
al.’s discovery of high amounts of EBOV cRNA and mRNA in semen from EVD survivors strongly 
suggests the presence of replicating virus in seminal fluid cells.33 Instead, because evolutionary rates 
are dependent on replication and mutation rates, as well as selective pressures, the reduced EBOV 
evolutionary rate could be related to reduced selection within immune-privileged sites such as the 
testes rather than reduced replication. 
Diallo et al. indicates that one explanation for EBOV persistence that cannot be ruled out is 
that the survivor was sub-clinically re-infected with EBOV following recovery.  However, this is 
unlikely because there has not yet been a documented, laboratory-confirmed case of EBOV 
reinfection.7  Similarly, in every study, blood samples that were collected concurrently with semen 
samples from EVD survivors tested negative by RT-PCR, which indicates the lack of an acute 
infection.  The lower-than-expected number of mutations observed in the EBOV genome from 
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persistent samples also renders it unlikely that this survivor is a subject of an undetected chain of 
human-to-human transmission among acute cases. 
Genomic techniques have been implemented alongside traditional epidemiological methods 
to investigate clusters of EVD that cannot be temporally, geographically, or epidemiologically linked 
to any known existing acute EVD cases.  Multiple studies have employed genome sequencing to 
characterize uncertain sources of infection, with direct human-to-human transmission suggested by 
high sequence similarities between EBOV samples from a survivor and the new, acute case.7,14-16,39,45,48,49  
In almost all cases of EBOV transmission that implicated a recovered survivor, sexual transmission 
via persistently-infected semen was the most suspected route.  Given the link between EBOV RNA 
detection and infectious viral particles described in the virologic studies above, combined with EBOV 
genomic analyses, sexual transmission from a survivor poses a plausible risk for initiating subsequent 
cases of EVD.  However, cases resulting from this transmission route appear to be few, as this route 
has been suggested in fewer than twenty reports.  All of the cases of potential sexual transmission 
from a survivor described male-to-female transmission, with no evidence of female-to-male 
transmission. This is consistent with the lack of conclusive evidence of EBOV persistence in vaginal 
fluids. 
However, it is important to note that not every sexual exposure with an EVD survivor 
necessarily results in sexual transmission. Christie et al. and Mate et al. described molecular evidence 
of sexual transmission from a male, EVD survivor, resulting in a new, acute case of EVD.14,15  The 
survivor also reported multiple instances of unprotected vaginal intercourse with another woman, 
which took place around the same time as the survivor’s contact with the acute EVD case.  The other 
woman did not develop EVD, and serologic testing for antibodies was negative, indicating no prior 
EBOV infection.  This inconsistency suggests that there may be other undescribed factors that place 
some people at a higher risk of contracting persistence-derived EVD from a survivor. 
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With regards to age and persistence, we found that age was a statistically significant predictor 
of EBOV RNA persistence in semen, which confirms the findings from two other cohort studies.  
Soka et al. and Fischer et al. first described a significant association between the age of the survivor 
and persistence of EBOV RNA in semen, with men over 40 years old more likely to have detectable 
EBOV RNA in seminal fluids.22,41  In contrast, Sissoko et al. did not detect a significant association for 
age and persistence.9  However, the small sample size of this study (n=26), in contrast to Fischer et al. 
(n=149) and Soka et al. (n=429), could explain this discrepancy. Moreover, the participants in Sissoko 
et al.’s study skewed towards the younger ages (median=31 years, IQR 26-40 years).  These two factors 
suggest that the study may have had insufficient statistical power to detect a significant association 
between older men and persistence of EBOV RNA in semen.  Taken together, these findings hint 
that older age is a potential determinant of EBOV persistence, and our analysis also finds that older 
age is significantly correlated with a longer length of persistence.  While age may be a proxy for other 
risk factors, this finding is plausible due to age-related changes in immune functioning, as immune 
senescence from natural aging may allow for persistence of EBOV into immune-privileged sites such 
as the testes.59 
A final concern to consider in revising clinical guidelines for EVD survivors relates to reports 
of intermittent detection of EBOV RNA by RT-PCR in multiple cohort studies.23,24,30,36  From our 
sample of 300 survivors, for which individual RT-PCR results were provided, we estimate that over 
30% of participants received a negative RT-PCR result for a semen sample followed by a positive 
result weeks or months later. Over 12% of participants even received two negative RT-PCR results 
prior to a positive result.  We also found that studies that reported intermittent results observed a later 
average day post-EVD onset of the last positive RT-PCR sample and also followed survivors for a 
longer period of time, compared to studies that did not report intermittent results.  The high rate of 
intermittent results in select studies could potentially be explained by increased difficulties in detecting 
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EBOV RNA as time passes, since Ct values have been shown to increase over time and approach the 
threshold of positivity set at Ct=40.6 Another possible explanation is that because studies with high 
rates of intermittent results followed survivors for a longer period of time, they were better able to 
capture patterns of intermittent detection, compared to other studies that may have stopped following 
survivors after a single negative RT-PCR result was received.  This explanation is further supported 
by the right-censoring observed in the data from 5 studies, who reported participants who were still 
positive by RT-PCR for EBOV RNA by the time the study ended.22,30,35,41,57 For instance, Sissoko et al. 
reported 3 individuals who were still positive for EBOV RNA by their last semen sample.9 Further 
testing of seminal fluids may have revealed either an intermittent pattern or an even longer duration 
of persistence.  
 
Limitations 
There are a few limitations to our review. Due to the constraints of having only one reviewer, 
selection of studies during the initial screening process may be subject to bias. For similar reasons, a 
validity assessment was performed in lieu of the more time-intensive GRADE process, which could 
mean that the inclusion of some of the final selected studies may not have been fully validated.  Some 
of the same individuals were reported in different studies (e.g. Christie et al. and Mate et al., or 
Rodriguez et al. and Rowe et al.).  Where possible, we corrected for this to avoid instances of the same 
individual contributing multiple times to estimates such as average duration.  However, there remains 
a small chance that a few individuals were double-counted.  
Our analyses were limited by our lack of access to individual-level data. Some analyses, such 
as those conducted for intermittent detection of EBOV RNA and for the association between age 
and persistence, were limited to publications that included subject-level data. A few cohort studies 
that were included in this review also did not consistently report variance data for our primary outcome 
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of interest, the duration of EBOV persistence. For instance, Subtil et al. reported only a minimum and 
maximum for duration of EBOV persistence rather than providing data on the variance.31  
Finally, we focused our attention on EBOV persistence in semen, vaginal fluids, and rectal 
samples because we were interested in the relation between EBOV persistence and sexual 
transmission. Contact with urine, fecal matter, or other bodily fluids not included in this review may 
also occur during sexual activity. Few studies estimated EBOV RNA persistence in these bodily fluids, 
so it is unlikely that this exclusion would have had a significant impact on our analyses.4,5,8,35,38 
 
Conclusions 
EBOV RNA has been detected in the seminal fluids of an EVD survivor for up to 40 months 
post-EVD onset.  After synthesizing all published evidence from 42 studies, representing nearly 2,000 
male survivors, the average duration of EBOV RNA in semen was 370 days post-EVD onset. Given 
these results, we suggest that the WHO consider revising their current recommendation that EVD 
survivors who have not had their semen tested practice safer sex for at least 12 months.  Our review 
indicates that persistence of EBOV RNA is related to an increased risk of sexual transmission of 
EBOV. Due to reports of intermittent detection of EBOV RNA, especially among survivors who 
experience EBOV persistence for over a year, we recommend that at least two negative RT-PCR 
results be received before declaring the survivor’s seminal fluid to be cleared of EBOV RNA.  Finally, 
we report that age is a potential determinant of EBOV persistence, with older age associated with a 
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Supplementary Table 1. Key search terms used and their combinations. The search strategy 
described below was used for Ovid(Medline). The search terms were subsequently adapted to suit 
the syntax of each database. 
 
Questions 1 & 2 Search Terms 
How long do Ebola virus 
and Ebola viral RNA persist 
in semen, vaginal, and rectal 
fluids, by sex? Is the 
persistence of Ebola viral 
RNA related to sexual 
transmission of EBOV? 
1. exp Ebola virus/ OR exp Hemorrhagic Fever, Ebola/  
2. (Ebola or EBOV or ebolavirus).ti,ab,kw.  
3. 1 OR 2 
4. exp semen/ OR exp rectum/ OR exp vagina/ 
5. semen.ti,ab,kw. OR seminal.ti,ab,kw. OR testes.ti,ab,kw. 
OR vagina*.ti,ab,kw. OR cervix.ti,ab,kw. OR 
cervical.ti,ab,kw. OR faeces.ti,ab,kw. OR feces.ti,ab,kw. 
OR fecal.ti,ab,kw. OR rectum.ti,ab,kw. OR rectal.ti,ab,kw. 
OR anus.ti,ab,kw. OR anal.ti,ab,kw. 
6. 4 OR 5 
7. 3 AND 6 
Question 3  
Does consistent and correct 
condom use reduce 
transmission of Ebola virus? 
1. exp Ebola virus/ OR exp Hemorrhagic Fever, Ebola/  
2. (Ebola or EBOV or ebolavirus).ti,ab,kw. 
3. 1 OR 2 
4. exp condom/ OR exp contraception, barrier/ OR exp 
safe sex 
5. condom.ti,ab,kw. OR barrier method.ti,ab,kw. OR safe* 
sex.ti,ab,kw. 
6. 4 OR 5 
7. 3 AND 6 
Questions 4 & 5  
How long after the 
resolution of EVD-related 
symptoms does a male 
partner need to use a latex 
condom with his male or 
female sexual partners? For 
how long, following the 
resolution of symptoms, 
should a man who recovered 
from EVD continue to have 
his semen tested? 
1. exp Ebola virus/ OR exp Hemorrhagic Fever, Ebola/  
2. (Ebola or EBOV or ebolavirus).ti,ab,kw. 
3. 1 OR 2 
4. exp sexually transmitted diseases/ OR exp coitus/ 
5. coitus.ti,ab,kw. OR sex.ti,ab,kw. OR sexual*.ti,ab,kw. OR 
intercourse.ti,ab,kw. OR penetrative.ti,ab,kw. OR 
penetration.ti,ab,kw. 
6. 4 OR 5 





Supplementary Table 2. Validity Assessment of Included Studies 
 
Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 




N/A; the study's 
purpose was to 
develop a 
mathematical model 




The model was fitted to data 
from weekly incidence of 
confirmed and probable 
cases in Sierra Leone (2014-
2015) from the WHO 
patient database. 
N/A Yes. Aim: "to investigate the potential impact of 
convalescent sexual transmission on the 
transmission dynamics in general, and on the tail 
of the epidemic in particular, to understand how 
long that vigilance might remain critical." 





assay, with positive results 
confirmed by a second RT-
PCR targeting viral 
nucleoprotein sequences. 
The Ct* cut-off for positive 
results was <40. 
Yes, duplicate-
tested 
Yes. The aim was to investigate "questions about 
the longterm persistence of Ebola virus in semen 





yes, in accordance 




Positive result by 
postmortem buccal swab 
tested by RT-PCR for 
deceased patient, or RT-
PCR of blood samples for 
living patients 
Unclear, but 
likely yes for 
living patients 
Yes. Aim: to detail a new chain of transmission 
occurring in Sierra Leon 4 months after the the 
last reported case. 
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Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 
sexual transmission or transmission from 
survivors? 




Collected blood samples or 
buccal swaps; positive if RT-




Yes. Aim: to use genome sequencing to "identify 
unconventional transmission chains involving 
body fluids, including semen" 
Barnes et 
al (2017) 
Yes, serum and 
blood samples were 
collected and tested 
daily from day 7 to 
day 30 post-
symptom onset, then 
semen samples from 
day 32 to day 244 
RT-PCR assay, with positive 
results for Ct values <40; 
also viral isolation by tissue 
culture 
Unclear Yes. Aim: to "[utilize] reverse-transcription 
quantitative polymerase chain reaction (RT-
qPCR) and deep sequencing to determine 
concentration of viral RNA, replicative capacity, 
and viral evolution in blood and semen of a 
single EVD patient over 110 days of illness" 
Bausch et 
al (2007) 
Yes, samples were 
placed into cryovials 
and stored at 
ambient temperature 
for <6 hours before 
being stored in 
liquid nitrogen 
ELISA antigen positive or 
RT-PCR positive; 
considered to be 
convalescent if they were 
previously a confirmed clase, 
but whose ELISA antigen 
and RT-PCR results had 
reverted to negative 
Yes, duplicate-
tested by both 
culture and real-
time RT-PCR 
Not exactly sexual transmission. Aim: "To better 
understand the precise modes of transmission, 
we sampled various clinical specimens from 
patients as well as from environmental surfaces" 
 
 50 
Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 





Yes, samples were 
tested within 1 day 
RT-PCR positive results Unclear Yes. Aim: "use epidemiological and genomic data 
to investigate the source of the second Liberian 





Positive result by RT-PCR Unclear Yes. Aim: " describes the investigation by the 
Government of Liberia and international 
response partners of the source of Liberia’s latest 
Ebola case and discusses the public health 
implications of possible sexual transmission of 
Ebola virus" 
Deen et al 
(2017) 
Yes, specimens were 
refrigerated for no 
longer than 3 days 
RT-PCR assays were 
performed that targeted 
EBOV NP and VP40 gene 
targets. A specimen was 
considered positive if the 
NP and VP40 gene targets 
were both detected within 
40 cycles of replication. 
Unclear Yes. Aim: "describes the participants’ 
characteristics at entry in the cohort of male 
survivors of EVD whose semen was tested by 




N/A; the study's 
purpose was to 





RT-PCR positive results N/A Yes. Aim: "describe a series of EBOV 
transmission events with evidence of 






RT-PCR positive results Unclear Yes. Aim: "report on an Ebola virus disease 
(EVD) survivor who showed Ebola virus in 
seminal fluid 531 days after onset of disease" 
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Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 





N/A; the study's 
purpose was to 
investigate 
epidemiological links 
of a cluster of new 
cases 
Positive laboratory result for 
Ebola virus antigen by 
reverse transcriptase 
qualitative PCR (RT-PCR) 
detection of virus RNA or 
by detection of anti-Ebola 
IgM antibodies 
N/A Not exactly sexual transmission. Aim: "Case 
investigations were done to ascertain previous 
contact with cases of Ebola virus disease or 
infection with Ebola virus." 




N/A N/A Yes. Aim: "to estimate the current number of 





yes, as this person 
was hospitalized 
Positive by viral culture Unclear Yes. This was a case report that also happened to 
describe EBOV isolated from convalescent 
semen specimens 





EVD," likely positive by 
RT-PCR 
Unclear Yes. Aim: " to assess long-term clinical, 
psychosocial,and viral outcomes in EVD 





RT-PCR positive results Unclear Yes. Aim: "To characterize the clinical sequelae 
in survivors and to assess whether they can 




N/A; the study's 
purpose was to 
assess the efficacy of 
detecting EBOV in 
semen and to 
determine the 
N/A N/A Yes. Aim: "We assessed the efficiency of 
detecting Ebola virus in semen samples by 
molecular diagnostics and the stability of Ebola 




Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 
sexual transmission or transmission from 
survivors? 
stability of EBOV in 
ex vivo semen  
Fisher et 
al (2017) 
Yes, semen was 
tested for EBOV 
RNA within 2 days 
of collection 
Samples were considered 
positive if either target gene 
(GP or NP) was detected by 
RT-PCR 
Unclear Yes. Aim: " describes the investigation by the 
Government of Liberia and international 
response partners of the source of Liberia’s latest 
Ebola case and discusses the public health 






RT-PCR assay, with positive 
results for Ct values <40 
Samples were 
retested if Ct 
values were 37-
40 
Yes. Aim: "to better inform necessary protective 
measures for health-care providers, behavioural 
modification advice for survivors" 




N/A N/A Yes. Aim: "to predict epidemic trends and 
evaluate intervention measure efficacy following 
the 2014 EVD epidemic in West Africa" 




Positive result by RT-PCR Unclear Yes. Aim: to investigate possible transmission of 





Positive result by RT-PCR Unclear Yes. Aim: "to assess the presence and duration of 
EBOV and viral RNA in semen and other body 
fuids of EVD survivors" 
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Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 
sexual transmission or transmission from 
survivors? 




N/A N/A Yes. Aim: "to compute the probability of the end 
of an Ebola virus disease epidemic, accounting 
for sexual transmission and underascertainment 
of cases" 
Lee et al 
(2017) 
N/A; the study's 
purpose was to 
report on 
recrudescence events 
in West Africa 
Recrudescent Ebola was 
defined as "reappearance of 
at least one confirmed case 
of EVD in a country where 
the end of EVD had been 
declared in advance" 
N/A Yes. Aim: "to review all known recrudescence 
events in West Africa occurring during the 
period 2014–2016" 




N/A N/A Yes. Aim: " to understand how the [West African 
epidemic was affected by various transmission 
routes which include contact with infections, 






Viral culture Unclear Not specifically Ebola, but the study was a case 
report on sexual transmission of the related 
Marburg virus 
Mate et al 
(2015) 
N/A; the study's 
purpose was to use 
genomic data to 
demonstrate sexual 
transmission from a 
survivor 
Positive result by RT-PCR N/A Yes. Aim: to use genomic analysis to provide 
evidence of sexual transmission of EBOV and 




Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 




N/A; the study's 
purpose was to 




Positive result by RT-PCR Unclear Not exactly from survivors. Aim: to investigate 
two Ebola virus RT-PCR discordant mother-
child pairs to suggest the need for RT-PCR 






For antibody specimens: 
"548 enzyme-linked 
immunosorbent assay units 
(EU) per milliliter was used 
as the cutoff for positivity"; 
For semen specimens: 
positive result by RT-PCR 
Unclear Yes. Aim: "describes the investigation by the 
Government of Liberia and international 
response partners of the source of Liberia’s latest 
Ebola case and discusses the public health 






Positive result by RT-PCR Unclear Yes. Aim: " to report an EVD survivor with 
preexisting HIV infection, whose semen was 
positive for Ebola virus RNA 565 days after 






EBOV isolation by viral 
culture, as well as using 
ELISA and IgM antibodies 
for viral 
antigen detection by ELISA 
Unclear Yes. Aim: "To describe the clinical 
manifestations of viral hemorrhagic fever, and to 







Positive laboratory result for 
Ebola virus antigen by 
reverse transcriptase 
qualitative PCR (RT-PCR) 
Unclear Yes. Aim: "to determine whether EBO virus is 
still present in body fluids of convalescent 
patients after clinical symptoms subside, and if 
so, what the duration of virus persistence is" 
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Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 
sexual transmission or transmission from 
survivors? 
detection of virus RNA or 
by viral culture 




Positive result by RT-PCR No, but the 
authors 
attempted to 
select 2 controls 
of the same sex 
as and close in 
age to the 
convalescent 
Yes. Aim: "to describe the clinical course of 
convalescence following EHF, determine 
whether body fluids contain EBO virus, and 
monitor household contacts for evidence of 
secondary transmission from the convalescents" 
Sissoko et 
al (2017) 
Yes, "We processed 




collection at the 
European mobile 
laboratory (EMLab) 
unit in Coyah" 
Positive result by RT-PCR Unclear Yes. Aim: "to use biostatistical modelling to 
describe the dynamics of Ebola virus RNA load 





Positive result by RT-PCR Unclear Not exactly about survivors. Aim: to investigate 
the case of a 9-month-old infant died from Ebola 
virus (EBOV) disease with unknown 




Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 
sexual transmission or transmission from 
survivors? 





by the MHSP were 
stored and 
transported at –20°C 
or colder to the 
Tappita Ebola virus 
disease laboratory in 
Nimba County. 
Upon receipt in the 
laboratory, 
specimens were 
maintained at –20°C 
or colder until 
testing" 
Positive result by RT-PCR Unclear Yes. Aim: "describe Liberia’s national semen 
testing programme for Ebola virus, present 
preliminary semen testing results, and report 
sexual risk behaviours" 




Positive result by RT-PCR Unclear Yes. Aim: "report new evidence of long-term 





yes, as this person 
was placed under 
quarantine 
Positive result by RT-PCR 
or viral isolation by culture 
Unclear Yes. Aim: "report follow-up of a man who 
recovered from EVD and was monitored for 165 
days after he was declared Ebola-free" 




Positive result by RT-PCR, 
with a Ct cutoff for 
positivity of ≤40.9 
Unclear Yes. Aim: "This study modeled the presence of 
Ebola virus RNA in the semen of male Ebola 




Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 






Detection of antibodies to 
GP, NP and VP40 proteins 
and of EBOV RNA in 
semen by PCR 
Unclear Yes. Aim: "to quantify individual risk of exposure 
of contact persons to EVD cases; to measure the 
presence of antibodies to EBOV; to look for 
EBOV RNA in semen of adult seropositive 
men" 





transported as soon 
as possible or 
maintained at 4 
degrees Celsius and 
shipped overnight 
on frozen cold packs 
to CDC. The 
majority of the 
specimens were 
processed within 0–
3 days; however a 
few were processed 
5–8 days after 
collection. Only one 
specimen that was 
collected 290 days 
post symptom onset 
was frozen prior to 
virus culture" 
Positive result by RT-PCR; 
cycle threshold (Ct) values 
<40 were considered 
positive; viral isolation by 
culture was also performed 
Unclear Yes. Aim: "[to investigate] the duration of Ebola 
virus (EBOV) RNA and infectious EBOV in 




Study Acceptable time 
delay between 
sample collection 




Case definition & method 






Was the aim relevant to human-to-human 
sexual transmission or transmission from 
survivors? 
Zeng et al 
(2016) 
N/A; the study's 
purpose was to 
assess the viability of 
rhesus monkeys as 
an animal model for 
EBOV persistence 
N/A N/A Yes. Aim: "to provide an animal model that 
demonstrates EBOV persistence is associated 
with ongoing replication in the presence of an 





Supplementary Table 3. Data for Weighted Average Calculation for Length of Persistence of EBOV RNA in Semen 
 
Reference No. of Patients No. of Patients 
with Positive 
Sample (%) 
Mean Time Between Disease Onset and 
Last Positive Sample 
Weight 
Abel et al (2017) 188 15 190.4 +/- 155.1*  0.41964286 
Fischer et al (2017) 149 13 771.9 +/- 100.9 0.33258929 
Rodriguez et al (1999), 
Rowe et al (1999) 
5 4 85.8 +/- 17.2 0.01116071 
Sissoko et al (2017) 26 19 149.6 +/- 91.2 0.05803571 
Sow et al (2016) 68 8 118.9 +/- 79.9 0.15178571 
Uyeki et al (2016) 5 5 184.6 +/- 75.3 0.01116071 
Barnes et al (2017) 1 1 110 0.00223214 
Bausch et al (2007) 1 1 40 0.00223214 
Christie et al (2015), 
Mate et al (2015) 
1 1 199 0.00223214 
Diallo et al (2016) 1 1 531 0.00223214 
Green et al (2016) 1 1 128 0.00223214 
Purpura et al (2017) 1 1 579 0.00223214 
Srinivas et al (2016) 1 1 179 0.00223214      
Weighted Average 370.3149554 Note: * denotes that the value was measured as days since discharge from ETC 




Supplementary Table 4. Data for Analysis of Age & Duration of EBOV RNA Persistence in 




Assay Age Latest Day After ADisease 
Onset: Positive Sample 
Abel et al (2017) Semen RT-PCR 56 511 
Abel et al (2017) Semen RT-PCR 26 467 
Abel et al (2017) Semen RT-PCR 29 209 
Abel et al (2017) Semen RT-PCR 37 90 
Barnes et al (2017) Semen RT-PCR 34 110 
Christie et al (2015), 
Mate et al (2015) 
Semen RT-PCR 46 199 
Diallo et al (2016) Semen RT-PCR 56 531 
Fischer et al (2017) Semen RT-PCR 47 965 
Fischer et al (2017) Semen RT-PCR 54 849 
Fischer et al (2017) Semen RT-PCR 34 737 
Fischer et al (2017) Semen RT-PCR 36 905 
Fischer et al (2017) Semen RT-PCR 38 676 
Fischer et al (2017) Semen RT-PCR 46 560 
Fischer et al (2017) Semen RT-PCR 43 762 
Fischer et al (2017) Semen RT-PCR 36 761 
Fischer et al (2017) Semen RT-PCR 46 734 
Fischer et al (2017) Semen RT-PCR 44 828 
Fischer et al (2017) Semen RT-PCR 42 749 
Fischer et al (2017) Semen RT-PCR 43 750 
Fischer et al (2017) Semen RT-PCR 41 759 
Green et al (2016) Semen RT-PCR 21 128 
Purpura et al (2017) Semen RT-PCR 48 579 
Rodriguez et al (1999) Semen RT-PCR 25 101 
Rodriguez et al (1999) Semen RT-PCR 27 82 
Rodriguez et al (1999) Semen RT-PCR 29 63 
Rodriguez et al (1999) Semen RT-PCR 33 63 
Sissoko et al (2017) Semen RT-PCR 40 254 
Sissoko et al (2017) Semen RT-PCR 45 168 
Sissoko et al (2017) Semen RT-PCR 35 251 
Sissoko et al (2017) Semen RT-PCR 18 177 
Sissoko et al (2017) Semen RT-PCR 33 407 
Sissoko et al (2017) Semen RT-PCR 26 233 
Sissoko et al (2017) Semen RT-PCR 30 158 
Sissoko et al (2017) Semen RT-PCR 46 168 
 
 61 
Sissoko et al (2017) Semen RT-PCR 19 184 
Sissoko et al (2017) Semen RT-PCR 28 177 
Sissoko et al (2017) Semen RT-PCR 27 57 
Sissoko et al (2017) Semen RT-PCR 32 94 
Sissoko et al (2017) Semen RT-PCR 32 72 
Sissoko et al (2017) Semen RT-PCR 28 103 
Sissoko et al (2017) Semen RT-PCR 40 38 
Sissoko et al (2017) Semen RT-PCR 35 61 
Sissoko et al (2017) Semen RT-PCR 18 72 
Sissoko et al (2017) Semen RT-PCR 55 73 
Sissoko et al (2017) Semen RT-PCR 25 95 
Sow et al (2016) Semen RT-PCR 48 276 
Sow et al (2016) Semen RT-PCR 28 30 
Sow et al (2016) Semen RT-PCR 27 56 
Sow et al (2016) Semen RT-PCR 27 61 
Sow et al (2016) Semen RT-PCR 48 182 
Sow et al (2016) Semen RT-PCR 19 93 
Sow et al (2016) Semen RT-PCR 37 99 
Sow et al (2016) Semen RT-PCR 58 218 






Supplementary Table 5. Studies Eligible for Analysis of Intermittent Detection Data 
 
Reference Number of people 
with fluctuating 
results 
Number of people with 2 –




Abel et al (2017), 
Subtil et al (2017) 
8 0 15 
Barnes et al (2017) 0 0 1 
Christie et al 
(2015), Mate et al 
(2015) 
0 0 1 
Emond et al 
(1977) 
0 0 1 




78 36 252 
Purpura et al 
(2017) 
1 1 1 
Sissoko et al 
(2017) 
0 0 19 
Total 95 38 303 













     




Up from Last 
Positive to Last 
Sample 




- + -         66 10 
Day After 
Disease Onset 
397 453 463         
RT-PCR 
Result 
+ - + - -     240 21 
Day After 
Disease Onset 




- + - - -     285 251 
Day After 
Disease Onset 






- + -         201 131 
Day After 
Disease Onset 










725 737 779 926 975     
RT-PCR 
Result 





648 660 732 905 954     
RT-PCR 
Result 















610 624 713 762 910 958   
RT-PCR 
Result 
+ - + - - - - 327 236 
Day After 
Disease Onset 
643 657 734 781 802 922 970 
RT-PCR 
Result 
- + + - 




707 719 749 791       
RT-PCR 
Result 
- - + - 




























          Total 
Length of 
Follow-Up 
Length of Follow-Up 






+ + + - - 212 134 
Day After 
Disease Onset 
32 66 110 180 244 
Christie et 
al (2015), 




+ - -     35 35 
Day After 
Disease Onset 





+ + - - - 71 49 
Day After 
Disease Onset 





+ - -     84 84 
Day After 
Disease Onset 
254 N/A 338     
RT-PCR 
Result 





168 N/A 270     
RT-PCR 
Result 





251 N/A 336     
RT-PCR 
Result 











+ - -     68 68 
Day After 
Disease Onset 
168 N/A 236     
RT-PCR 
Result 















177 N/A 282     
RT-PCR 
Result 





57 N/A 243     
RT-PCR 
Result 









+ - -     196 196 
Day After 
Disease Onset 
72 N/A 268     
RT-PCR 
Result 
+ - -     139 139 
Day After 
Disease Onset 
103 N/A 242     
RT-PCR 
Result 
+ - -     187 187 
Day After 
Disease Onset 
38 N/A 225     
RT-PCR 
Result 







61 N/A 118     
 
 
